EGFR and non-small cell lung carcinoma: The detection of mutations in the kinase domain of the epidermal growth factor receptor provides guidance for advanced non-small cell lung cancer, and EGFR tyrosine kinase inhibitors are the standard first-line therapy [1,2,4,5].